Get the Stockscreener App
128.13
1.88%
2.36
After Hours:
127.49
-0.64
-0.50%
Ascendis Pharma A S Adr stock is traded at $128.13, with a volume of 279.20K.
It is up +1.88% in the last 24 hours and down -10.19% over the past month.
Ascendis Pharma AS is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.
See More
Previous Close:
$125.77
Open:
$124.52
24h Volume:
279.20K
Relative Volume:
0.46
Market Cap:
$7.66B
Revenue:
$343.51M
Net Income/Loss:
$-530.29M
P/E Ratio:
-11.32
EPS:
-11.3176
Net Cash Flow:
$-610.17M
1W Performance:
+1.07%
1M Performance:
-10.19%
6M Performance:
-6.61%
1Y Performance:
+35.37%
1-Day Range:
$122.13
$129.31
1-Week Range:
$120.77
$129.31
52-Week Range:
$86.55
$161.00
Ascendis Pharma A S Adr Stock (ASND) Company Profile
Name
Ascendis Pharma A S Adr
Sector
Industry
Phone
-
Address
-
Ascendis Pharma A S Adr Stock (ASND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-23 | Initiated | Jefferies | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Neutral |
| Apr-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-04-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-03-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-20-22 | Initiated | Goldman | Buy |
| Aug-30-22 | Resumed | Berenberg | Buy |
| Mar-28-22 | Resumed | Wedbush | Outperform |
| Mar-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-14-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-06-22 | Initiated | Cowen | Market Perform |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Oct-20-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-30-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-11-21 | Resumed | Stifel | Buy |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Mar-20-20 | Initiated | Oppenheimer | Outperform |
| Oct-11-19 | Initiated | Morgan Stanley | Overweight |
| Mar-25-19 | Initiated | Evercore ISI | Outperform |
| Jan-24-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-24-19 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Jun-26-18 | Initiated | Stifel | Buy |
| Apr-02-18 | Reiterated | Leerink Partners | Mkt Perform |
| May-11-17 | Initiated | JP Morgan | Overweight |
| Mar-09-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Feb-09-17 | Initiated | Credit Suisse | Outperform |
| Sep-26-16 | Initiated | Wedbush | Outperform |
View All
Ascendis Pharma A S Adr Stock (ASND) Latest News
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug - Benzinga
Nothing is Better Than Ascendis Pharma A/S ADR (ASND) stock at the moment - SETE News
Financial Health Report: Ascendis Pharma A/S ADR (ASND)’s Ratios Tell a Tale - The Dwinnex
Ascendis Pharma A/S ADR’s Banking’s 100-Day Moving Average at 134.03: Will the Stock Break Through? - The InvestChronicle
Stock Market Recap: Ascendis Pharma A/S ADR (ASND) Concludes at 132.05, a -5.10 Surge/Decline - The Dwinnex
The Ascendis Pharma A/S ADR (ASND) had a good session last reading, didn’t it? - US Post News
Stocks Showing Rising Market Leadership: Ascendis Pharma ADR Earns 83 RS Rating - Investor's Business Daily
Top investors say Ascendis Pharma A/S ADR (ASND) ticks everything they need - SETE News
Results from Ascendis Pharma A/S ADR (ASND) show risk - US Post News
Sei Investments Co. Sells 81,615 Shares of Ascendis Pharma A/S (NASDAQ:ASND) - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $191.00 - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Holdings Lifted by Evolutionary Tree Capital Management LLC - MarketBeat
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - MSN
Investor’s Delight: Ascendis Pharma A/S ADR (ASND) Closes Strong at 148.88, Up 1.56 - The Dwinnex
Ascendis Pharma launches $300 million public offering - Investing.com
Ascendis Pharma A/S (NASDAQ:ASND) Shares Acquired by Seven Eight Capital LP - MarketBeat
Analysts review Ascendis Pharma A/S ADR’s rating - Knox Daily
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs - Yahoo Finance
Analyzing Edgewise Therapeutics Inc (EWTX) After Recent Trading Activity - Knox Daily
Ascendis Pharma A/S ADR (ASND) did well last session? - US Post News
Ascendis Pharma shares retain Outperform rating, Evercore ISI lifts target citing potential in new patient starts - Investing.com
Prepare Yourself for Liftoff: Ascendis Pharma A/S ADR (ASND) - SETE News
Oppenheimer raises Ascendis Pharma shares, maintains Outperform rating - Investing.com India
Goldman Sachs raises Ascendis Pharma stock price target on study success - Investing.com India
Jefferies lifts Ascendis Pharma target to $179 on trial data - Investing.com
Barclays maintains BioMarin at Overweight with $110 target - Investing.com
Why This Small Biotech Is Hammering BioMarin Today - Investor's Business Daily
Positive topline data supports Ascendis Pharma stock, analyst highlights potential for weekly injection advantage. - Investing.com India
Ascendis Pharma reaffirms stock target, buy rating on study success - Investing.com
Ascendis Pharma reports growth in achondroplasia trial - Investing.com India
Citi maintains buy on Ascendis with $178 target amid trial data - Investing.com
Market Insights: Ascendis Pharma A/S ADR (ASND)’s Notable Gain of 0.78, Closing at 113.81 - The Dwinnex
Ascendis Pharma A/S ADR (ASND)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Closing Figures Unveiled: Ascendis Pharma A/S ADR (ASND) Drop -1.94, Closes at 116.84 - The Dwinnex
Citi maintains Ascendis Pharma stock at Buy, positive outlook ahead of pivotal trial data - Investing.com India
A better buy-in window may exist right now for Ascendis Pharma A/S ADR (ASND) - SETE News
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
TD Cowen maintains Buy on Ascendis, keeps $157 target - Investing.com
Ascendis Pharma A/S ADR (ASND) requires closer examination - US Post News
Stock Performance Spotlight: Ascendis Pharma A/S ADR (ASND) Ends the Day at 119.50, Down by -11.27 - The Dwinnex
Jefferies cuts Ascendis share price target amid hGH market pressure - Investing.com
Goldman Sachs cuts Ascendis Pharma shares target, maintains Buy rating - Investing.com
Ascendis Pharma stock target cut, retains rating amid Skytrofa sales miss - Investing.com
Earnings call: Ascendis Pharma reports mixed Q2 2024 results, forecasts growth - Investing.com
Biotech Makes A Bearish Move On Drug-Pricing Fiasco - Investor's Business Daily
Taking on analysts’ expectations and winning: Ascendis Pharma A/S ADR (ASND) - SETE News
Ascendis Pharma stock tanks on earnings miss - Investing.com
Ascendis Pharma A/S ADR (ASND) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Ascendis Pharma A/S ADR (ASND) Stock: Navigating a Year of Volatility - The InvestChronicle
JPMorgan raises Ascendis Pharma stock target on drug approval - Investing.com
Can you still get a good price for Ascendis Pharma A/S ADR (ASND) Shares at this point? - US Post News
Ascendis Pharma A S Adr Stock (ASND) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):